Background {#Sec1}
==========

Long non-coding RNAs (lncRNAs) play important roles in the regulation of transcription and post-transcriptional processes of coding and non-coding RNAs. Different mechanisms of function have been reported for lncRNAs including guiding chromatin modifiers to specific genomic loci, sequestering transcription factors, allosteric modulation of transcriptional regulatory proteins, alteration of nuclear domains, modulation of translation, modulation of mRNA stability, and working as competing endogenous RNAs \[[@CR1]--[@CR3]\]. Investigations on the role of lncRNAs in normal development and their aberrant functionality in different diseases underscore their importance in cellular phenomena such as genomic imprinting, dosage compensation, pluripotency, and differentiation commitment \[[@CR4]\]. These findings have proven lncRNAs to be important molecules with significant functions.

Functional experiments to investigate the roles of lncRNAs are highly needed. A plethora of experiments has been devised and implemented to investigate the function of lncRNAs. These experiments can be divided into three categories. The first category includes RNA interference (RNAi) and antisense oligonucleotides that aim at the destruction of transcribed lncRNA. The second category includes clustered regularly interspaced short palindromic repeats (CRISPR)- mediated interference (CRISPRi) and activation (CRISPRa) that target the regulatory regions of the gene for tuning the level of its transcription. And the third category includes programmable nucleases including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas9 (CRISPR-associated protein-9 nuclease) that are used for the ablation of the gene. Different criteria have been described for proper selection of a functional experiment for a given transcript \[[@CR5]\]. These criteria are mainly related to the location of the target lncRNA gene and its position relative to other genes, the location of its regulatory regions \[[@CR5]\], and sub-cellular localization of lncRNA. Knockdown of a lncRNA as a strategy to study its function has at least two limitations: (1) the incomplete depletion of the transcript due to the nature of the approach and the nuclear localization of lncRNA, and (2) possible off target effects \[[@CR6], [@CR7]\]. When transcription of the target gene is regulated in a complicated fashion, application of CRISPRi and CRISPRa techniques may also fail to inhibit or induce the lncRNA transcription \[[@CR7]\]. For many lncRNAs with complex transcriptional profile and regulatory regions, the CRISPR/Cas9 mediated ablation of the locus can act as a very specific and powerful tool to study their functions.

The colon cancer associated transcript 1 (CCAT1) lncRNA is upregulated in various human malignant and pre-malignant tissues \[[@CR8]\] including colon adenocarcinoma \[[@CR9]\], gastric carcinoma \[[@CR10]--[@CR12]\], ovarian cancer \[[@CR13]\], hepatocellular carcinoma \[[@CR14]\], and other kinds of cancers. CCAT1 is known to be involved in various normal and pathologic cellular processes such as proliferation, migration and metastasis \[[@CR15]--[@CR18]\]; it was shown to also act as a competing endogenous RNA \[[@CR19], [@CR20]\], and a regulator of cMYC \[[@CR15], [@CR21]\]. However, due to the complexity of the processes that CCAT1 is known to control or contribute in, further investigations are required to clarify the exact molecular mechanism (s) by which this lncRNA acts. Gene knockdown procedures are helpful in delineating gene functions and RNAi \[[@CR20]--[@CR22]\] and antisense oligonucleotide \[[@CR16]\] techniques have so far been used to study the CCAT1 functions. But, RNAi and antisense techniques act mostly within the cytoplasm, while many lncRNAs, including CCAT1, function mainly inside the nucleus and hence these techniques are far from being highly efficient \[[@CR23]\].

In this work, we used three CRISPR/Cas9 mediated gene knockout strategies to deplete genomic CCAT1 transcription. The first strategy (herein named "CRISPR excision") involved the complete removal (excision) of a DNA segment encompassing an exon. In the second strategy, a DNA segment coding for a DNA reporter construct including transcription terminator, was inserted in an exonic region in CCAT1 genomic locus by homology-directed repair (HDR) mechanism (herein named "CRISPR HDR"). And in the final strategy, hereafter called "CRISPR du-HITI" standing for "CRISPR/Cas9 dual allele homology-independent targeted integration", we employed a modified version of CRISPR/Cas9 HITI \[[@CR24]\]. In this strategy, in each allele, the targeting fragment replaces the genomic region located between two double-strand breaks (DSBs) formed by Cas9. In addition, two alleles are targeted simultaneously by two different inserts, making it possible to select the targeted genomic locus by both alleles. We successfully applied and exploited these three knockout strategies and established model cell lines lacking CCAT1 lncRNA.

Results {#Sec2}
=======

Application of Three Different CRISPR/Cas9 Mediated Knockout Strategies Targeting the CCAT1 lncRNA {#Sec3}
--------------------------------------------------------------------------------------------------

In the human 8q24.21 gene desert region, the *CCAT1* gene (\~ 11.8 Kb) is located \~ 173 kb downstream of the cancer susceptibility 21 (*CASC21*), and \~ 31 kb upstream of the cancer susceptibility 19 (*CASC19*) gene loci. CCAT1 transcription is highly upregulated in the pre-malignant adenomatous polyps and malignant colorectal carcinoma \[[@CR8]\]. Two short and long isoforms of CCAT1 have been identified and it seems that the short isoform might be derived from the long isoform \[[@CR25]\]. The long isoform of CCAT1 is totally retained in the nucleus. However, all the experiments designed to explore CCAT1 functions have so far used either RNAi or antisense oligonucleotides. To develop colorectal adenocarcinoma cellular models that lack CCAT1 transcription, we used three different strategies to knockout *CCAT1*. Our aim here was to interfere with the normal function of CCAT1 by removing a segment of the gene important for the secondary structure of CCAT1, or by introducing a transcription termination signal within the *CCAT1* locus to cause a premature transcription termination.

The first strategy, that we here call "CRISPR excision", involves precise deletion of a genomic fragment using two sgRNAs (Fig. [1a](#Fig1){ref-type="fig"}). In this strategy, we used two sgRNAs to direct the endonuclease activity of Cas9 to either side of CCAT1 exon 1 (Fig. [1a](#Fig1){ref-type="fig"}). For this purpose, we used HT-29, SW-480, and HCT-116 cell lines. After a first round of transfection and selection we obtained 45 HT-29 clones. PCR from genomic DNA revealed that 7 clones had one copy of CCAT1 deleted and no clones were homozygous for this deletion. We therefore used the heterozygous clones for a second round of "CRISPR excision" and after transfection and selection we were able to identify 2 out of 50 clones which were homozygous knockouts for CCAT1 as verified by PCR analysis of genomic DNA and sequencing of the PCR product (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). RT-qPCR measurements of CCAT1 mRNA from the produced clones revealed a 370,000 fold (Fig. [2c](#Fig2){ref-type="fig"}) reduction of CCAT1 mRNA in the knockout clones compared to the wild-type cells. Previous reports achieved just a \~ 10 fold knockdown of CCAT1 in HT-29 cells using antisense oligonucleotides \[[@CR25]\].Fig. 1CRISPR/Cas9 knockout strategies for ablation of CCAT1 lncRNA gene. **a** "CRISPR excision". To delete a genomic fragment (here, exon 1) two sgRNAs are targetted to either side of the fragment. Non- homologous end joining of the two remaining parts of genomic DNA after Cas9-induced double-strand breaks (DSBs) results in the deletion of the genomic fragment. **b** "CRISPR HDR". In this strategy, using one sgRNA and Cas9-induced DSB in one region is followed by homology-directed repair using a reporter (CMV-PuroR-IRES2-EGFP) plus polyadenylation signal fragment (originated from a donor vector with homology arms). In this case, any transcript initiated from the first or second exon is confronted by a premature transcription termination. **c** "CRISPR du-HITI". This strategy uses two donor vectors without homology arms. Two vectors containing sgRNA+PAM are used as donors, one with EGFP expression cassette, and the other with a PuroR expression cassette. Use of two sgRNAs directs the Cas9 protein towards the two either end of exon 1 at both alleles. Endonuclease function of Cas9 results into deletion of a genomic fragment (here, exon 1) from each allele, and linearization of two donor vectors. Selection of cells for their green color and their resistance to puromycin dihydrochloride results into cells with their both alleles targetted and knocked outFig. 2Confirmation of the *CCAT1* knockouts and qPCR analysis. **a** *CCAT1* wild-type locus and its knockout alleles by "CRISPR excision", "CRISPR du-HITI", and "CRISPR HDR". Location of sgRNA binding sites (sgRNA b. s.), primers to perform PCR analysis (Table [4](#Tab4){ref-type="table"}), and inserted fragments are shown. "CRISPR excision" of exon I (Ex. I) is confirmed by a 409 bp PCR fragment using two primers at either side of exon I. "CRISPR du-HITI" is confirmed by a PCR product of 495 bp using a primer in the insert and the other in the flanking region. The insert used for "CRISPR du-HITI" could express EGFP (bright green) or puroR (light blue) under CAG promoter. In this strategy when two alleles are targetted simultaneously, then the cells show both green fluorescence and resistance to puromycin dihydrochloride. "CRISPR HDR" was performed on exon II using an insert containing DSred (red in color), CMV, puroR, IRES, GFP, PA (poly adenylation signal, purple in color). In "CRISPR HDR" strategy cells with only one targetted allele could show both green fluorescence and resistance to puromycin dihydrochloride. PCR analysis using a primer in the insert and the other in the flanking region results in a 1627 bp product (Table [4](#Tab4){ref-type="table"}). **b** Gel electrophoresis of PCR fragments for wild-type (w.t.) (**a**), CRISPR excised (b; clone \# 20), "CRISPR du-HITI" knockout (c; clone \# 27), and "CRISPR HDR" alleles (e; clone \# 2i) according to the maps in panel A. Lane d is DNA size marker. **c** CCAT1 transcript relative to β-actin levels in wild-type and "CRISPR excision" knockout HT-29 colon adenocarcinoma cells. **d** CCAT1 transcript relative to β-actin levels in wild-type and "CRISPR HDR" knockout HCT-116 colon adenocarcinoma cells. **e** CCAT1 transcript relative to β-actin levels in wild-type and "CRISPR du-HITI" knockout SW-480 colon adenocarcinoma cells. In panels, C, D, and E the absolute copy number for CCAT1 and β-actin transcripts were quantified based on the related standard curves, and for three series of cell line cDNAs, the quantity of the CCAT1 transcript divided by the quantity of the β-actin was plotted. The statistical differences between the wild-type and knockout cell lines are analyzed by Mann-Whitney *U* test

The second strategy that we here refer to as "CRISPR HDR" involved the insertion of a reporter gene and a transcription termination signal in CCAT1 genomic locus using a single sgRNA and a donor vector with homology arms (Fig. [1b](#Fig1){ref-type="fig"}). We targeted the initial regions of the second exon since it has been reported that this region acts as a promoter for transcripts that originate from exon 2. The inclusion of a transcription termination signal in exon 2 ensures that the transcription of transcripts originating from exon 1 or from the proximal region of exon 2 will cease prematurely. Our reporter construct includes a green fluorescence protein (GFP) gene and DNA for the resistance to puromycin dihydrochloride to facilitate selection of correctly modified cells. In the first attempt of selection of puromycin resistant and green colonies, we selected 6 SW-480 and 14 HCT-116 clones. The selected clones were clonally expanded and were subjected to DNA extraction, PCR validation, and Sanger sequencing (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). These analyses indicated that 4 out of 6 selected SW-480 and 8 out of 14 selected HCT-116 clones harbored the desired fragment insertions. RT-qPCR analysis of these clones revealed statistically significant lower expression levels (2 fold reduction) of CCAT1 compared to the control cells (Fig. [2d](#Fig2){ref-type="fig"}).

Our third strategy, here referred as "CRISPR du-HITI" comprises the deletion of a genomic fragment encompassing exon I of CCAT1 using two sgRNAs and insertion of two reporters and transcription termination signals using two donor vectors without homology arms (Fig. [1c](#Fig1){ref-type="fig"}). Cloning of the donor vectors used for this strategies was less laborious than that used for "CRISPR HDR" and the presence of a selection made the screening of correctly modified cells more practical compared to the "CRISPR excision" approach. In addition, using this strategy it is possible to mostly identify homozygous deletion of the target gene by virtue of selection for both GFP and puromycin. In the selected clones one allele will be therefore have the GFP reporter and the other allele the PuroR cassette. Furthermore, in this strategy, it is also possible to delete large genomic fragments and replace them with different reporter cassettes. In the first attempt of transfection, single cell isolation, and clonal expansion, we were able to acquire 6 clones of HCT-116 cells that had permanent green fluorescence phenotype and puromycin resistance (Fig. [2](#Fig2){ref-type="fig"}). The knock-in was verified by PCR analysis that showed the insertion of the desired fragments (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). These clones had statistically significant lower expression levels (27 fold reduction) of CCAT1 compared to the control cell line (Fig. [2e](#Fig2){ref-type="fig"}).

*CCAT1* Knockout Cells Display Dysregulation of Genes Involved in Several Biological Processes {#Sec4}
----------------------------------------------------------------------------------------------

We used RNA-Seq to evaluate changes in the transcriptional landscape associated with inactivation of CCAT1 gene in colon adenocarcinoma cells (CCAT1 KO cells). We tested for enriched GO (Gene Ontology) terms in the wild-type versus knockout transcriptomes. Differentially expressed (DE) transcripts (log2-fold change \> 1 and \< − 1), statistically significant (*p* \< 0.05) for enrichment in the CCAT1 KO cells, were identified. GO analysis indicated that a total of 332 genes were associated with some biological processes, molecular functions, or cellular components. The enriched GO terms in the category of molecular function, biological process, and cellular components are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 1Enriched gene ontology terms in the CCAT1 wild-type versus CCAT1 knockout transcriptomes derived from differentially expressed genes (in the category of molecular function)IDTermGene Count*p* Value^a^GO:0004867serine-type endopeptidase inhibitor activity92.50E-04GO:0016491oxidoreductase activity126.60E-04GO:0005515protein binding1719.60E-03GO:0008236serine-type peptidase activity52.30E-02GO:0004879RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding42.30E-02GO:0004252serine-type endopeptidase activity103.10E-02GO:0015485cholesterol binding43.30E-02GO:0004029aldehyde dehydrogenase (NAD) activity33.30E-02GO:0032810sterol response element binding23.40E-02GO:0003727single-stranded RNA binding43.70E-02GO:0016620oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor34.10E-02GO:0004715non-membrane spanning protein tyrosine kinase activity44.40E-02GO:0005506iron ion binding74.70E-02GO:0003779actin binding104.90E-02^a^Only GO terms with *p* value of less than 0.05 are shownTable 2Enriched gene ontology terms in the CCAT1 wild-type versus CCAT1 knockout transcriptomes derived from differentially expressed genes (in the category of biological process)IDTermGene Count*p* Value^a^GO:0042493response to drug174.50E-05GO:0055114oxidation-reduction process241.30E-04GO:0031295T cell costimulation71.80E-03GO:0008283cell proliferation153.00E-03GO:0030522intracellular receptor signaling pathway53.40E-03GO:0010951negative regulation of endopeptidase activity83.90E-03GO:0090090negative regulation of canonical Wnt signaling pathway95.60E-03GO:0008285negative regulation of cell proliferation156.00E-03GO:0006805xenobiotic metabolic process69.20E-03GO:0051897positive regulation of protein kinase B signaling61.20E-02GO:0030449regulation of complement activation41.30E-02GO:0006081cellular aldehyde metabolic process31.30E-02GO:0048013ephrin receptor signaling pathway61.40E-02GO:0001822kidney development61.40E-02GO:0007612learning51.40E-02GO:0032091negative regulation of protein binding51.40E-02GO:0046685response to arsenic-containing substance31.90E-02GO:0007568aging81.90E-02GO:0060337type I interferon signaling pathway52.10E-02GO:0042632cholesterol homeostasis52.10E-02GO:0043524negative regulation of neuron apoptotic process72.20E-02GO:0006954inflammatory response132.30E-02GO:0016477cell migration82.40E-02GO:0006636unsaturated fatty acid biosynthetic process32.50E-02GO:0032570response to progesterone42.60E-02GO:0038083peptidyl-tyrosine autophosphorylation42.80E-02GO:0008360regulation of cell shape72.80E-02GO:0032526response to retinoic acid43.00E-02GO:0002223stimulatory C-type lectin receptor signaling pathway63.00E-02GO:0003057regulation of the force of heart contraction by chemical signal23.30E-02GO:0045785positive regulation of cell adhesion43.30E-02GO:0042127regulation of cell proliferation83.40E-02GO:0031668cellular response to extracellular stimulus33.50E-02GO:0009615response to virus63.50E-02GO:0030325adrenal gland development33.80E-02GO:0071222cellular response to lipopolysaccharide63.90E-02GO:0030154cell differentiation144.30E-02GO:0014070response to organic cyclic compound44.70E-02GO:0070668positive regulation of mast cell proliferation24.90E-02GO:0060675ureteric bud morphogenesis24.90E-02GO:0006991response to sterol depletion24.90E-02^a^Only GO terms with *p* value of less than 0.05 are shownTable 3Enriched gene ontology terms in the CCAT1 wild-type versus CCAT1 knockout transcriptomes derived from differentially expressed genes (in the category of cellular component)IDTermGene Count*p* Value^a^GO:0070062extracellular exosome784.50E-06GO:0005615extracellular space421.30E-04GO:0005829cytosol781.10E-03GO:0005576extracellular region424.20E-03GO:0031234extrinsic component of cytoplasmic side of plasma membrane65.50E-03GO:0002102podosome47.20E-03GO:0005856cytoskeleton149.80E-03GO:0030687preribosome, large subunit precursor41.20E-02GO:0031528microvillus membrane33.90E-02GO:0005886plasma membrane834.10E-02GO:0072562blood microparticle74.20E-02GO:0034666integrin alpha2-beta1 complex24.90E-02^a^Only GO terms with *p* value of less than 0.05 are shown

*CCAT1* Knockout Cells Show Reduced Anchorage-Independent Growth {#Sec5}
----------------------------------------------------------------

The role of CCAT1 in anchorage-independent growth was analyzed by soft agar colony formation assay. It is known that inhibition of entosis enhances anchorage-independent growth in soft agar assay and promotes tumorigenesis \[[@CR26]\]. HT-29, HCT-116, and SW-480 wild-type and *CCAT1* KO cells were cultured in soft agar and allowed to form colonies over a period of 3 weeks. The wild-type HT-29 cells formed an average of 35 ± 4 colonies per microscopic fields, while *CCAT1* KO HT-29 cells formed an average of 24 ± 3 colonies. The average colony size of wild-type SW-480 colonies was 20.86 ± 0.9, while the average size of *CCAT1* KO SW-480 cells was 0.4 ± 0.08 pixel squared (Fig. [3a](#Fig3){ref-type="fig"}).Fig. 3*CCAT1* knockout cells lose the capacity for anchorage-independent growth. **a** Representative images of soft agar colony formation assay for wild-type and *CCAT1* KO cell lines and evaluation of colony count and colony area in these lines. **b** MTT assay in HT-29, HCT-116, and SW-480 wild-type and *CCAT1* KO cell lines performed 2 h and 24 h after seeding. The statistical differences between the wild-type and knockout cell lines are analyzed by Mann-Whitney test. The scale bars in panel A denote 200 μm

MTT assay was performed to investigate whether the decrease in the number and size of soft agar colonies is associated with changes in the metabolic activity of *CCAT1* KO cells. MTT assay performed 2 h after cell seeding did not reveal any significant changes between KO and wild-type cells. However, MTT assay after 24 h exhibited a significant decrease in the absorbance readings in two *CCAT1* KO cell lines compared to the wild-type cells (Fig. [3b](#Fig3){ref-type="fig"}). This suggested that the decreased MTT absorbance reading after 24 h might be caused by the lower number of cells in the knockout groups, while this effect is not evident when cells are cultured only for 2 h and have not started to divide \[[@CR27], [@CR28]\].

Discussion {#Sec6}
==========

With the increasing discovery of lncRNAs, there is a growing need for application of functional studies to reveal their biological roles. Similar to protein-coding genes, approaches aiming at expression inhibition are useful for studying lncRNA biological functions. However, the two approaches routinely exploited for this purpose, i.e. RNA interference and antisense strategies, are not as efficient for lncRNAs with nuclear localization. Furthermore, these techniques are associated with poor depletion of the target gene, off-target effects, and technical variations. Applying newly developed genome editing approaches to alter lncRNA genomic locus so that the related lncRNA becomes non-functional is a good alternative. However, considering the non-coding nature of lncRNAs, changes at the corresponding genomic loci need to be large enough to adversely affect the structure and biological function of the expressed RNA. For example, a simple excision followed by NHEJ may not provide enough structural changes in a given lncRNA. Here, we used three different CRISPR-mediated KO strategies, i.e. "CRISPR excision", "CRISPR HDR", and "CRISPR du-HITI", to alter the *CCAT1* locus in different colorectal adenocarcinoma cell lines.

"CRISPR excision" using two sgRNAs to delete a genomic fragment of lncRNA genes has already been reported \[[@CR29]--[@CR31]\]. For the implementation of this strategy, no donor vectors are used and thus, no reporter genes are inserted into the genome. As a result, the selection of KO cells becomes a tedious job. "CRISPR HDR", in contrast, uses donor vectors and thus, enables the user to select the targeted cells based on fluorescence and/or resistance to an antibiotic \[[@CR30], [@CR31]\]. However, in this strategy, homology arms need to be cloned into the donor vector. The "CRISPR du-HITI" which doesn't rely on the presence of homology arms, makes the selection of the target cells easier (Fig. [1](#Fig1){ref-type="fig"}). This approach enables us to direct fabrication of KOs so that each cell with both antibiotic resistance and fluorescence phenotypes is easily selected as a dual allele KO.

*CCAT1* KO cells created in this study were verified by genomic PCR, sequencing, and RT-qPCR (Fig. [2](#Fig2){ref-type="fig"}). Since the qPCR forward and reverse primers were complementary to exon 1 and exon 2, respectively, we did not expect to have any amplification products from "CRISPR excision" and "CRISPR du-HITI" KO cells. In these two approaches, exon 1 was completely removed. However, in "CRISPR HDR" the first segment of exon 2 (after the complementary sequence to reverse primer) was targeted with a fragment containing reporter/transcription termination signal. Thus, an amplification product was expected. This could explain the presence of RNA which was still measurable in these cells, and that only the two-fold CCAT1 decrease was observed (Fig. [2d](#Fig2){ref-type="fig"}). These three cell lines express different levels of CCAT1, the highest level of CCAT1 is detected in HT-29, while both SW-480 and HCT 116 express low levels of CCAT1 (Additional file [2](#MOESM2){ref-type="media"}: Figure S2). Presence of a residual RNA (the cycle threshold for knockout CCAT1 in all cell lines) could also be attributed to the cancerous nature of these cells and the presence of CCAT1 extra copies and pseudogenes in the genome.

The *CCAT1* KO cells were subjected to RNA-seq, soft agar colony formation assay, and MTT analysis. These cells displayed differential expression of a number of genes (Tables [1](#Tab1){ref-type="table"}-[3](#Tab3){ref-type="table"}). Accordingly, soft agar colony formation and MTT assays were able to verify that cell proliferation is negatively affected in the *CCAT1* KO cells (Fig. [3](#Fig3){ref-type="fig"}). This finding in turn, is in accordance with the previous reports that CCAT1 suppression affects genes that are involved in the regulation of cell proliferation \[[@CR32]\].

Conclusions {#Sec7}
===========

In conclusion, we characterized here three CRISPR/Cas9 mediated strategies that provide effective tools for lncRNA functional surveys. Furthermore, the *CCAT1* KO cell lines created in this study can be used for further functional analyses to reveal the battery of functions of CCAT1. The du-HITI strategy introduced in this study is easy to implement and can be applied for the generation of homozygous cells knockout for a specific lncRNA of interest.

Methods {#Sec8}
=======

Cell Culture {#Sec9}
------------

All cell lines were purchased from the National Cell Bank of Iran (Pasteur Institute, Iran) and cultured as recommended by the ATCC. Three colorectal adenocarcinoma cells were used, which differed based on microsatellite stability (MS) and CpG island methylator phenotype (CIMP). HT-29 cells are microsatellite stable (MSS), and CIMP high, SW-480 cells are MSS and CIMP low, and HCT-116 cells show microsatellite instability (MSI) and are CIMP high \[[@CR33]\]. HT-29 and SW-480 cells were cultured in RPMI (Biowest, France) supplemented with 10% FBS (Gibco, USA), 50 U/ml penicillin and 50 μg/ml streptomycin (Sigma-Aldrich, USA) at 37 °C in 5% CO2. HCT-116 cells were cultured in DMEM (Gibco, USA) containing 10% FBS and penicillin-streptomycin (50/50 U/ug/ml) at 37 °C in a 5% CO2 environment.

DNA Constructs and Gene Targeting {#Sec10}
---------------------------------

The single guide RNA (sgRNA) sequences targeting different segments of *CCAT1* gene were designed using the CRISPR design tool (<http://crispr.mit.edu/>). Three vectors of pX459 (containing U6 promoter-sgRNA insertion site-sgRNA scaffold, and CAG promoter-Cas9-T2A- puromycin N-acetyltransferase gene-bovine growth hormone polyadenylation signal), pX460--1 (containing U6 promoter-sgRNA insertion site-sgRNA scaffold, and CAG promoter-enhanced GFP (EGFP)-bovine growth hormone polyadenylation signal), and pX461--1 (containing U6 promoter-sgRNA insertion site-sgRNA scaffold, and CAG promoter-puromycin N-acetyltransferase (PuroR)-bovine growth hormone polyadenylation signal) were used for sub-cloning of sgRNAs. For this purpose, oligonucleotides (Table [4](#Tab4){ref-type="table"}) containing the sgRNA expressing sequence and BbsI steaky ends were synthesized (Macrogen Inc., South Korea), annealed, phosphorylated and ligated into the BbsI-digested and gel purified (using Gel Extraction Kit; DENAzist Asia Co., Iran) vectors. For "CRISPR du-HITI" targeting vectors, the PAM sequence was also introduced after the sgRNA expressing sequence.Table 4Oligonucleotides used in this studyGeneSequence (5′ to 3′)Product (bP)ApplicationCCAT1 (NR_108049.1)F: CTGACAACATCGACTTTG\
R: CTCACAGTTTTCAAGGGA\
Probe: FAM-CTTAGCCATACAGAGCCAACCTG-BHQ1108qPCRF: CGATCGttctgttttcaatggggatt\
R: TCGAGggagctgcggataacagcatat546Cloning of left homology armF: CTAGTCCCgcatcacagctactgtcaaccc\
R: ATCCCCtcaaagcacttctgtggtagga832Cloning of right homology armForward-1: CACATGGCTCCCATCACACTA\
Reverse-1: GGGGGAAGAAATTTAAGATGCACA1298 (w.t.) 409 (ko)PCR confirmation of CRISPR Excision knockout alleleForward-2: CACGCAGATCACATGACCCT\
Reverse-2: CGGGCCATTTACCGTAAG1627 (ko)PCR confirmation of CRISPR HDR knockout alleleForward-2: CACGCAGATCACATGACCCT\
R: AAACgatggagctgcggataacagC843 (w.t.)PCR confirmation of CRISPR HDR wild-type alleleForward-3: CGGGCCATTTACCGTAAG\
Reverse-1: GGGGGAAGAAATTTAAGATGCACA495 (ko)PCR confirmation of CRISPR du-HITI knockout alleleF: CACCGaatcggagtccaaagccatt\
R: AAACaatggctttggactccgattC--sgRNA (downstream of Exon 1)F: CACCGataatggaggggatttacgt\
R: AAACacgtaaatcccctccattatC--sgRNA (upstream of Exon 1)F: CACCGctgttatccgcagctccatc\
R: AAACgatggagctgcggataacagC--sgRNA (Exon 2)F: CACCGaatggctttggactccgatttgg\
R: AAACccaaatcggagtccaaagccattC--sgRNA bait (+PAM) (downstream of Exon 1)b-ActinF: TGCAGAAGGAGATCACTG\
R: CTTGCTGATCCACATCTG\
Probe: CY5-AAGATCAAGATCATTGCTCCTCCTGA-BHQ2141qPCR

The vector used for "CRISPR HDR" targeting contained left homology arm (546 bp), DsRed2, herpes simplex virus thymidine kinase polyadenylation signal, CMV promoter, PuroR, IRES2, EGFP, SV40 polyadenylation signal, and right homology arm (832 bp).

According to Table [5](#Tab5){ref-type="table"}, constructs (verified by Sanger sequencing; Macrogen Inc., South Korea) were used for transfection of colorectal adenocarcinoma cell lines using Lipofectamine 2000 reagent (Thermo Fisher Scientific, USA), Exgen 500 (Thermo Fisher Scientific, USA) or Polyethylenimine (Sigma-Aldrich, USA). For "CRISPR excision" and removal of *CCAT1* exon 1, 2 weeks after transfection cells were cultured in low density, and individual colonies (50 colonies) were allowed to expand and then selected by PCR analysis. Selection of colonies for "CRISPR du-HITI" and "CRISPR HDR" was performed by their GFP expression and resistance to puromycin dihydrochloride (Sigma-Aldrich, USA). All "CRISPR excision", "CRISPR du-HITI", and "CRISPR HDR" individual colonies were verified by genomic DNA isolation, PCR analysis, and Sanger sequencing (Macrogen Inc., South Korea).Table 5DNA constructs used in this studyConstructFeaturesApplicationpX459_2hU6 promoter- sgRNA (downstream of CCAT1 Exon 1)-sgRNA scaffold-CAG promoter-Cas9-T2A- PuroR-bGH polyACRISPR Excision\
CRISPR du-HITIpX459_3hU6 promoter- sgRNA (upstream of CCAT1 Exon 1)-sgRNA scaffold-CAG promoter-Cas9-T2A- PuroR-bGH polyACRISPR Excision\
CRISPR du-HITIpX459_13hU6 promoter- sgRNA (CCAT1 Exon 2)-sgRNA scaffold-CAG promoter-Cas9-T2A- PuroR-bGH polyACRISPR HDRpHD_4317_CCAT1 E2 HAsExon 2 LHA-DsRed2-HSV TK polyA-CMV promoter --PuroR-IRES2-EGFP-SV40 polyA-Exon 2 RHACRISPR HDRpX460_11hU6 promoter-sgRNA (downstream of CCAT1 Exon 1) plus PAM-sgRNA scaffold-CAG promoter-EGFP-bGH polyACRISPR du-HITIpX461_11hU6 promoter-sgRNA (downstream of CCAT1 Exon 1) plus PAM-sgRNA scaffold-CAG promoter-PuroR-bGH polyACRISPR du-HITI*hU6* human U6 promoter, *sgRNA* single guide RNA, *PuroR* puromycin N-acetyltransferase, *bGH* bovine growth hormone polyadenylation signal, *SV40 polyA* SV40 polyadenylation signal, *IRES* internal ribosome entry site

Genomic DNA Isolation and Analysis {#Sec11}
----------------------------------

Genomic DNA was isolated with the Genomic DNA Isolation Kit I (DENAzist Asia Co., Iran) from wild-type and knockout cell lines and was subjected to PCR amplification (Fig. [2](#Fig2){ref-type="fig"}). PCR-amplified bands after clean-up and reaction recovery (DENAzist Asia Co., Iran), were subjected to Sanger sequencing (Macrogen Inc., South Korea).

Reverse Transcription Quantitative PCR {#Sec12}
--------------------------------------

Total RNA was isolated from wild-type and knockout cell lines using Total RNA Isolation Kit (DENAzist Asia Co., Iran). The quality and quantity of extracted RNA were evaluated using gel electrophoresis and a 2000 Nanodrop spectrophotometer (Thermo Scientific, USA). Total RNA (1 μg) was reverse transcribed using random hexamer primers and MMLV reverse transcriptase (Thermo Fisher Scientific, USA). To quantify the level of transcripts for CCAT1 and β-actin, quantitative RT-PCR reactions containing Premix Ex Taq (Probe qPCR) master mix (Takara, Japan), 2 μl cDNA template and each primer at 500 nM and 100 nM probe (dual-labeled hybridization probes, 5'FAM-3'BHQ1-labeled for CCAT1 and 5'CY5--3'BHQ2 for β-actin) in a 20 μl reaction volume, were carried out in a Rotor-Gene Q real-time PCR cycler (Qiagen, USA). Amplification steps were: 95 °C for 5 min, followed by 40 cycles of 94 °C for 30 s, 57.5 °C for 30 s, and 72 °C for 30 s. To confirm the identity of PCR products, Sanger sequencing was performed (Macrogen Inc., South Korea).

Amplified fragments were sub-cloned in pTZ57R or pGATA plasmids and their serial dilution was used to make standard curves. Each dilution was subjected to three PCR reactions and real-time readings were performed in triplicate. Then, the log of copy numbers was plotted against cycle threshold (Ct) numbers. For each qPCR reaction, efficiency (E) was calculated from the calculated slope of standard curves, generated using 5 fold serially diluted solutions of plasmids, according to the following equation: E = (10^--1/slope-1^) × 100%. All standard curves were linear in the analyzed range with an acceptable correlation coefficient (R^2^). Absolute copy number for CCAT1 and β-actin transcripts were quantified based on the related standard curves. For three series of cDNAs, the quantity of the target transcript (CCAT1) was divided by the quantity of the reference gene (β-actin) and plotted.

RNA Sequencing and GO Analysis {#Sec13}
------------------------------

Tuxedo pipeline \[[@CR34]\] was performed for differential expression analysis of whole transcriptome sequencing results of HT-29 wild-type and knockout cell lines. The differentially expressed genes from the study were input for assessing the enrichment. For data precision and consistency, we adjusted *p*-value to correct the data, fold change was declared at least ±1 fold and *p*-value \< 0.05 was regarded as significant. Compared to the wild-type cell lines, 182 differentially expressed genes were selected and association of gene list to Gene Ontology (GO) terms was performed using the new GO category (GO Direct) of the latest released version of DAVID web tool (DAVID 6.8 Oct. 2016), (<http://david.ncifcrf.gov>) \[[@CR35], [@CR36]\].

Soft Agar Colony Formation and MTT Assays {#Sec14}
-----------------------------------------

The methodology previously described was followed \[[@CR37]\]. To evaluate the anchorage-independent growth of *CCAT1* KO cell lines, cells were plated at 2 × 10^4^ in DMEM/F12 containing 5% horse serum, penicillin/streptomycin, and 0.3% 2-hydroxyethyl agarose (Sigma, USA) (with 0.6% 2-hydroxyethyl agarose underlay) in flat-bottom non-treated six-well plates (SPL, South Korea). By overlaying 1 ml of 0.3% 2-hydroxyethyl agarose/medium solution onto the existing feeder layer, the feeding procedure was performed for three times (once a week). After 3 weeks, the colonies were fixed with 4% paraformaldehyde (Electron Microscopy Sciences, USA) in PBS for 30 min and stained with 0.5% methylene blue in ethanol for 30 min. The number and area of colonies were determined using NIH ImageJ software \[[@CR38]\].

To perform MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide) assay, Cells were seeded in a 96-well plate in three or more replicates (5000 cells/well). and MTT (to a final concentration of 0.5 mg/ml in culture medium) was added to each well after 2 or 24 h of seeding. The plate was incubated at 37 °C in dark for 3 h. Then, the media was discarded, 100 μl of DMSO was added to each well, incubated at room temperature in the dark for 15 min, and the color developed was measured at 590 nm using Epoch 2 microplate reader (BioTek Instruments Inc., USA).

Additional files
================

 {#Sec15}

Additional file 1:**Figure S1.** PCR validation of CCAT1 knockout cells. PCR amplification of wild-type (w.t.) and knockout (KO) alleles in different clones (different numbers) produce by CRISPR excision (A), CRISPR HDR (B), and CRISPR du-HITI (C) approaches are shown. Colonies 18, 19, and 20 in panel A are CCAT1 wild-type, heterozygous CCAT1 KO, and homozygous CCAT1 KO, respectively. In panel B, colonies 8e and 2i are heterozygous CCAT1 KO. In panel C, colony n5 is a homozygous CCAT1 KO. The primers used for PCR amplification are listed in Table [4](#Tab4){ref-type="table"}. M: DNA size marker, bp: base pair. (TIF 3887 kb) Additional file 2:**Figure S2.** Amplification curves for CCAT1 transcript in HT29, SW480, and HCT116 cells. The representative cycle thresholds (CTs) are shown for each cell line. The big difference in CT values indicates that the level of CCAT1 transcript in HT29 is much higher than that in SW480 and HCT116 cells. NTC: non-template control. (TIF 944 kb)

CCAT1

:   Colon cancer associated transcript 1

lncRNA

:   Long noncoding RNA

KO

:   Knockout

CRISPR

:   Clustered regularly interspaced short palindromic repeats

Cas9

:   CRISPR-associated protein-9 nuclease

HDR

:   Homology-directed repair

HITI

:   Homology-independent targeted integration

du-HITI

:   Dual allele HITI

RNAi

:   RNA interference

DSBs

:   Double-strand breaks

DE

:   Differentially expressed

RT

:   Reverse transcription

qPCR

:   Quantitative PCR
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